Unlike the COVID vaccine, longevity treatments should not be mandated by the government. Forcing people to live longer could be seen as dystopian and create partisan resistance. A better approach is to encourage voluntary adoption, allowing early adopters to demonstrate the benefits to skeptics over time.

Longevity medicine's explosion stems from: 1) long-term dissatisfaction with managed care, 2) COVID-19 increasing mortality awareness, 3) a post-pandemic demand for personalized care, and 4) the timely arrival of effective technologies like GLP-1s. Understanding this cultural context is key.

The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

While the wealthy can access expensive protocols involving diagnostics and lifestyle optimization, these offer only marginal benefits. True, effective longevity will not come from this but from validated, mass-produced biotech drugs that target the core mechanisms of aging.

By extending citizens' "healthspan," the demand for expensive late-stage Medicare services decreases. This argument reframes longevity from a purely medical issue to a key strategy for fiscal conservatives focused on reducing government spending.

Anti-aging treatments will pay for themselves by eliminating the enormous medical costs of late-life health problems. This creates a powerful economic imperative for governments to ensure universal access, countering the common fear that such therapies will only be available to the wealthy.

A centrist solution to high drug prices involves combining ideas from both political aisles. Oliver Libby suggests allowing Medicare to negotiate prices (a left-leaning idea) while also extending patent life for drug companies (a right-leaning idea), thus lowering costs without killing the incentive for innovation.

Without government action, longevity treatments will remain a luxury product for the ultra-wealthy. Federal involvement in funding, clinical trial support, and payer coverage is essential to democratize breakthroughs and make them accessible to everyone.

The common aversion to living to 120 stems from assuming extra years will be spent in poor health. The goal of longevity science is to extend *healthspan*—the period of healthy, mobile life—which reframes the debate from merely adding years to adding high-quality life.